Charles A. Carter

424 total citations
22 papers, 293 citations indexed

About

Charles A. Carter is a scholar working on Infectious Diseases, Internal Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Charles A. Carter has authored 22 papers receiving a total of 293 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 4 papers in Internal Medicine and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Charles A. Carter's work include Venous Thromboembolism Diagnosis and Management (4 papers), COVID-19 Clinical Research Studies (3 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (2 papers). Charles A. Carter is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (4 papers), COVID-19 Clinical Research Studies (3 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (2 papers). Charles A. Carter collaborates with scholars based in United States, Brazil and France. Charles A. Carter's co-authors include Jawed Fareed, My Hang V. Huynh, Thomas J. Meyer, Peter S. White, Vasilios A. Skoutakis, Fakiha Siddiqui, Miranda A.L. van Tilburg, Christopher J. White, George Dangas and Nodar Kipshidze and has published in prestigious journals such as Angewandte Chemie International Edition, Neurology and Physical Therapy.

In The Last Decade

Charles A. Carter

22 papers receiving 282 citations

Peers

Countries citing papers authored by Charles A. Carter

Since Specialization

Citations

This map shows the geographic impact of Charles A. Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles A. Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles A. Carter more than expected).

Fields of papers citing papers by Charles A. Carter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles A. Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles A. Carter. The network helps show where Charles A. Carter may publish in the future.

Co-authorship network of co-authors of Charles A. Carter

This figure shows the co-authorship network connecting the top 25 collaborators of Charles A. Carter. A scholar is included among the top collaborators of Charles A. Carter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles A. Carter. Charles A. Carter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neonatal Abstinence Syndrome in North Carolina: Incidence and Characteristics among Infants and Mothers 2022 ·North Carolina Medical Journal ·(unknown), (unknown), (unknown), Michael R. Jiroutek, Charles A. Carter	1
2	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations 2022 ·Clinical and Applied Thrombosis/Hemostasis ·(unknown), Omer Iqbal, Joseph M. Lewis, Charles A. Carter, Meharvan Singh, Fabio Lievano, (unknown), Walter Jeske, Cafer Adıgüzel, Grigoris Gerotziafas, Jawed Fareed	14
3	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination 2021 ·Clinical and Applied Thrombosis/Hemostasis ·(unknown), Omer Iqbal, Jeanine M. Walenga, Bruce Lewis, (unknown), Charles A. Carter, Meharvan Singh, Fabio Lievano, Alfonso Tafur, Eduardo Ramacciotti, Grigoris Gerotziafas, Walter Jeske, Jawed Fareed	33
4	Public Perceptions of Current COVID-19 Vaccinations. Results of a Pilot Survey 2021 ·Clinical and Applied Thrombosis/Hemostasis ·(unknown), (unknown), (unknown), Omer Iqbal, Fakiha Siddiqui, Nusrat Jabeen, Atul Laddu, Charles A. Carter, Jawed Fareed	3
5	Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020 2020 ·Clinical and Applied Thrombosis/Hemostasis ·Eduardo Ramacciotti, Ariane Vieira Scarlatelli Macedo, (unknown), Roberto Augusto Caffaro, Renato D. Lópes, João Carlos de Campos Guerra, Fernanda Andrade Orsi, Marcos Arêas Marques, Alfonso Tafur, Joseph A. Caprini, Andrew Nicolaides, Charles A. Carter, (unknown), Jawed Fareed	19
6	Viral Coagulopathy in Patients With COVID-19: Treatment and Care 2020 ·Clinical and Applied Thrombosis/Hemostasis ·N. Kipshidze, George Dangas, Christopher J. White, Nodar Kipshidze, Fakiha Siddiqui, Christopher R. Lattimer, Charles A. Carter, Jawed Fareed	59
7	Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version 2020 ·Clinical and Applied Thrombosis/Hemostasis ·(unknown), Eduardo Ramacciotti, Ariane Vieira Scarlatelli Macedo, Roberto Augusto Caffaro, Leandro Barile Agati, Fakiha Siddiqui, (unknown), Debra Hoppensteadt, Jawed Fareed, Charles A. Carter	3
8	Gender disparities in patient education provided during patient visits with a diagnosis of coronary heart disease 2019 ·Women s Health ·(unknown), (unknown), (unknown), Michael R. Jiroutek, Charles A. Carter	15
9	Integration of Biomedical and Psychosocial Treatments in Pediatrics Functional Gastrointestinal Disorders 2018 ·Gastroenterology Clinics of North America ·Miranda A.L. van Tilburg, Charles A. Carter	16
10	Formation and Reactivity of the Osmium(IV)-Cyanoimido Complex [OsIV(bpy)(Cl)3(NCN)]− 2001 ·Angewandte Chemie International Edition ·My Hang V. Huynh, Peter S. White, Charles A. Carter, Thomas J. Meyer	40
11	Formation and Reactivity of the Osmium(IV)-Cyanoimido Complex [OsIV(bpy)(Cl)3(NCN)]− 2001 ·Angewandte Chemie ·My Hang V. Huynh, Peter S. White, Charles A. Carter, Thomas J. Meyer	9
12	Safety and Acid-Suppressant Properties of Histamine₂-Receptor Antagonists for the Prevention of Stress-Related Mucosal Damage in Critical Care Patients 1989 ·DICP ·(unknown), Charles A. Carter, Lynda S. Welage	7
13	Drug Information Center Network: Need, Effectiveness, and Cost Justification 1987 ·Drug Intelligence & Clinical Pharmacy ·Vasilios A. Skoutakis, (unknown), Charles A. Carter, (unknown), (unknown), (unknown)	13
14	Dialyzability and Pharmacokinetics of Indomethacin in Adult Patients with End-Stage Renal Disease 1986 ·Drug Intelligence & Clinical Pharmacy ·Vasilios A. Skoutakis, Sergio R. Acchiardo, Charles A. Carter, (unknown), Arthur B. Straughn, Marvin C. Meyer	2
15	Leuprolide: A Gonadotropin-Releasing Hormone Analog for the Palliative Treatment of Prostatic Cancer 1986 ·Drug Intelligence & Clinical Pharmacy ·(unknown), Charles A. Carter, Vasilios A. Skoutakis, (unknown), (unknown), (unknown)	15
16	The Comparative Bioavailability of Liquid, Wax‐Matrix, and Microencapsulated Preparations of Potassium Chloride 1985 ·The Journal of Clinical Pharmacology ·Vasilios A. Skoutakis, Sergio R. Acchiardo, (unknown), Charles A. Carter, (unknown), A.N. Chremos	5
17	Terfenadine, a Nonsedating Antihistamine 1985 ·Drug Intelligence & Clinical Pharmacy ·Charles A. Carter, (unknown), (unknown), Vasilios A. Skoutakis, (unknown)	13
18	Ethotoin in seizures of childhood and adolescence 1984 ·Neurology ·Charles A. Carter, Richard A. Helms, Robert F. Boehm	6
19	Liquid and Solid Potassium Chloride: Bioavailability and Safety 1984 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Vasilios A. Skoutakis, Sergio R. Acchiardo, (unknown), Charles A. Carter	4
20	Energy Cost of Rehabilitation Calisthenics 1979 ·Physical Therapy ·(unknown), Masaaki Takahashi, Charles A. Carter, David H. Nielsen	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact